Emerging molecular therapies for the treatment of acute lymphoblastic leukemia

Monali Vasekar, Joshua E. Allen, Jamal Joudeh, David Claxton

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The improved molecular understanding of cancer initiation, progression, and therapeutic resistance has yielded several novel molecular events that are being targeted by emerging therapies. While the treatment of ALL is a success story in the pediatric population, achieving a sustained remission in the adult population remains an area of investigation. Nevertheless, certain therapies have significantly improved the overall survival for adult ALL patients that should continue to improve with the discovery of better molecular targets and targeted agents. Here, we discuss novel therapeutic options under clinical investigation for the treatment of Philadephia chromosome negative ALL including immunotherapy, monoclonal antibodies, and small molecules that may be used as single agent or adjuvant therapy in the management of adult ALL.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages341-358
Number of pages18
DOIs
StatePublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Emerging molecular therapies for the treatment of acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Vasekar, M., Allen, J. E., Joudeh, J., & Claxton, D. (2013). Emerging molecular therapies for the treatment of acute lymphoblastic leukemia. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 341-358). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-16